View a product list of Medtronic target drug delivery (TDD) products.
Drug infusion systems
SynchroMed™ II intrathecal pump
<p>The SynchroMed™ II programmable, implantable pump delivers drug to the intrathecal space via an implanted catheter.</p>
SynchroMed™ II pump is no longer available to order in the United States.
Please refer to SynchroMed™ III or contact your sales representative for more details.
Features
SynchroMed™ II pump
- Offered in two sizes (20 mL or 40 mL) to create efficient refill intervals
- Powerful long-lasting durability with diamond-like carbon coating that resists the wear from gear revolutions†
- Designed to last up to seven years at up to 0.9 mL/day flow rate
- ±0.3% repeatability — each pump precisely delivers a reliable and consistent amount of drug‡
- Allows safe full-body access to 1.5- and 3.0-Tesla MRI.§ The pump is designed to resume programmed therapy after the scan◊ and does not need to be emptied prior to a scan, minimizing drug waste and procedural steps
- Catheter acess port
- Catheter port
- Suture loop
- Reservoir fill port
Product reliability
Product performance data
See prospective, long-term multi-center registry study data for intrathecal drug delivery systems.
TM* Third-party brands are trademarks of their respective owners.
† Medtronic data on file.
‡ 95% confidence, 50% of the pumps have a flow rate repeatability of +/- 0.27% between successive 1 mL dispensed volumes within a refill cycle.
§ 
Under specific conditions. Refer to product labeling for full list of conditions.
◊ Requires interrogation to confirm pump status.
- Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304–1313.
- Hatheway J.A., Bansal M., Nichols-Ricker C.I. 2020. Systemic Opioid Reduction and Discontinuation Following Implantation of Intrathecal Drug-Delivery Systems for Chronic Pain: A Retrospective Cohort Analysis. Neuromodulation. 2020; 23: 961–969.
- Hatheway JA, et al. Systemic opioid elimination after implantation of an intrathecal drug delivery system significantly reduced health-care expenditures. Neuromodulation. 2015;18(3):207–13.
- Perruchoud et al. Management of Cancer-Related Pain With Intrathecal Drug Delivery: A Systematic Review and Meta-Analysis of Clinical Studies. Neuromodulation. 2022; S1094-7159(21)06969-5.
- Stearns et al. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Anesth Analg. 2020; 130(2):289–297.
- Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug related toxicity, and survival. J Clin Oncol. 2002;20:4040–4049.